Galectin Therapeutics Inc. (NASDAQ:GALT) – Stock analysts at Seaport Global Securities upped their Q4 2017 earnings per share (EPS) estimates for Galectin Therapeutics in a research report issued on Wednesday, Zacks Investment Research reports. Seaport Global Securities analyst V. Bernardino now expects that the company will post earnings of ($0.12) per share for the quarter, up from their previous estimate of ($0.13). Seaport Global Securities currently has a “Buy” rating and a $5.00 target price on the stock. Seaport Global Securities also issued estimates for Galectin Therapeutics’ FY2019 earnings at ($0.50) EPS, FY2020 earnings at ($0.32) EPS and FY2021 earnings at ($0.18) EPS.
A number of other research analysts also recently issued reports on the company. Roth Capital initiated coverage on Galectin Therapeutics in a report on Thursday, October 19th. They issued a “buy” rating and a $8.00 price target on the stock. ValuEngine upgraded Galectin Therapeutics from a “strong sell” rating to a “sell” rating in a report on Thursday, September 28th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company’s stock. Galectin Therapeutics presently has an average rating of “Hold” and an average target price of $4.63.
ILLEGAL ACTIVITY NOTICE: “Seaport Global Securities Comments on Galectin Therapeutics Inc.’s Q4 2017 Earnings (NASDAQ:GALT)” was posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this report on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The original version of this report can be accessed at https://ledgergazette.com/2017/11/21/q4-2017-eps-estimates-for-galectin-therapeutics-inc-lifted-by-analyst-galt-3.html.
Galectin Therapeutics (NASDAQ:GALT) opened at $3.05 on Friday. Galectin Therapeutics has a fifty-two week low of $0.81 and a fifty-two week high of $3.68.
Galectin Therapeutics (NASDAQ:GALT) last announced its quarterly earnings results on Tuesday, November 7th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.15) by $0.02.
A number of hedge funds have recently made changes to their positions in GALT. Vanguard Group Inc. grew its stake in Galectin Therapeutics by 18.2% during the 2nd quarter. Vanguard Group Inc. now owns 871,510 shares of the company’s stock worth $2,144,000 after buying an additional 134,165 shares during the last quarter. Advisor Group Inc. grew its stake in Galectin Therapeutics by 10.4% during the 2nd quarter. Advisor Group Inc. now owns 484,000 shares of the company’s stock valued at $1,191,000 after purchasing an additional 45,700 shares during the last quarter. Virtu KCG Holdings LLC grew its stake in Galectin Therapeutics by 24.4% during the 2nd quarter. Virtu KCG Holdings LLC now owns 107,203 shares of the company’s stock valued at $264,000 after purchasing an additional 21,008 shares during the last quarter. Northern Trust Corp grew its stake in Galectin Therapeutics by 4.4% during the 2nd quarter. Northern Trust Corp now owns 75,097 shares of the company’s stock valued at $185,000 after purchasing an additional 3,176 shares during the last quarter. Finally, KCG Holdings Inc. grew its stake in Galectin Therapeutics by 1.9% during the 1st quarter. KCG Holdings Inc. now owns 86,195 shares of the company’s stock valued at $198,000 after purchasing an additional 1,592 shares during the last quarter. Hedge funds and other institutional investors own 11.03% of the company’s stock.
Galectin Therapeutics Company Profile
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Galectin Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.